Take a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales in its once mighty diabetes franchise are sliding, while newer medicines such as its eczema and
There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another
